STOCK TITAN

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) to present at Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Live webcasts and archived replays will be available on the company's website.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present at the following investor conferences this month:

  • Jefferies London Healthcare Conference: Fireside chat on Wednesday, November 15 at 5:00 p.m. GMT
  • Evercore ISI HealthCONx Conference: Fireside chat on Wednesday, November 29 at 7:30 a.m. ET

Live webcasts of the Company presentations will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies. Akero's lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. EFX is currently being evaluated in two ongoing, 96-week Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Screening in the first two of three Phase 3 clinical trials began in September 2023, the SYNCHRONY Histology study and the SYNCHRONY Real-World study. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information.

Investor Contact:
Austin Murtagh
212.698.8696
IR@akerotx.com

Media Contact:
Sarah O’Connell
732.456.0092
soconnell@vergescientific.com


FAQ

What is the upcoming event for Akero Therapeutics, Inc. (AKRO)?

Akero Therapeutics, Inc. (AKRO) will be presenting at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference.

Where can I watch the live webcasts of the company presentations?

The live webcasts will be available through the investor relations section of Akero Therapeutics, Inc.'s website at www.akerotx.com.

Will there be archived replays of the company presentations?

Yes, archived replays will be available on the Company's website after the live webcasts.

What does Akero Therapeutics, Inc. (AKRO) specialize in?

Akero Therapeutics, Inc. (AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic disease.

When is the fireside chat at the Jefferies London Healthcare Conference?

The fireside chat is scheduled for Wednesday, November 15 at 5:00 p.m. GMT.

When is the fireside chat at the Evercore ISI HealthCONx Conference?

The fireside chat is scheduled for Wednesday, November 29 at 7:30 a.m. ET.

Akero Therapeutics, Inc.

NASDAQ:AKRO

AKRO Rankings

AKRO Latest News

AKRO Stock Data

1.36B
46.04M
5.77%
92.13%
11.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About AKRO

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.